Acadia Pharmaceuticals reported $0 in Loan Capital for its fiscal quarter ending in March of 2025.





Loan Capital Change Date
Acadia Pharmaceuticals USD 0 0 Mar/2025
ALKERMES USD 1.47B 5.38M Sep/2026
Alnylam Pharmaceuticals USD 2.11B 358.58M Sep/2026
Biogen USD 7.29B 1.7M Sep/2026
BioMarin Pharmaceutical USD 3.51B 12.96M Sep/2026
Bristol-Myers Squibb USD 41.85B 244M Sep/2026
Cara Therapeutics USD 0 0 Mar/2025
Cytokinetics USD 244.33M 3.87M Sep/2026
Eisai JPY 184.62B 19M Sep/2026
Eli Lilly USD 46.99B 872M Sep/2026
Incyte USD 28.42M 994K Jun/2026
J&J USD 35.8B 1.55B Sep/2026
Moderna USD 3.55B 2.95B Sep/2026
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Pfizer USD 60B 498M Sep/2026
Prothena USD 0 0 Dec/2024
PTC Therapeutics USD 536.27M 749K Sep/2026
Sarepta Therapeutics USD 699.39M 148.23M Sep/2026
Ultragenyx Pharmaceutical USD 1.13B 2M Jun/2026
Vanda Pharmaceuticals USD 3.15M 3.15M Dec/2024
Vertex Pharmaceuticals USD 3.5B 3.39B Sep/2026